Caplin Point Laboratories Ltd's Q4FY25 Quarter Results
- 16 May 2025
Result Summary
- Caplin Point Laboratories Ltd reported a 10.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.4%.
- Its expenses for the quarter were down by 6.5% QoQ and up 17.3% YoY.
- The net profit decreased 13.5% QoQ and increased 19.7% YoY.
- The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 15.9 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 470.51 | 524.32 | 400.68 | -10.3% | 17.4% |
Total Expenses | 324.54 | 347.05 | 276.71 | -6.5% | 17.3% |
Profit Before Tax | 145.97 | 177.27 | 123.97 | -17.7% | 17.7% |
Tax | 24.80 | 37.19 | 22.81 | -33.3% | 8.7% |
Profit After Tax | 121.23 | 140.07 | 101.24 | -13.5% | 19.7% |
Earnings Per Share | 15.90 | 18.20 | 13.30 | -12.6% | 19.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Caplin Point Laboratories Ltd is a pharmaceutical company primarily engaged in the development, manufacturing, and marketing of generic formulations and APIs. The company operates in the pharmaceuticals industry, focusing on producing a wide range of products that cater to various therapeutic segments. Caplin Point Laboratories has established a significant presence in emerging markets, notably in Latin America and Africa, where it exports a substantial portion of its products. As of the latest available information, no specific recent major developments have been highlighted for Caplin Point Laboratories Ltd.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Caplin Point Laboratories Ltd reported a total income of ₹470.51 crores. This represents a decline of 10.3% compared to the previous quarter (Q3FY25), where the total income was ₹524.32 crores. However, when compared year-over-year, there is an increase of 17.4% from Q4FY24, where the total income stood at ₹400.68 crores. The company's revenue performance shows variability over the quarters, with a notable annual growth trend.
Profitability
For Q4FY25, Caplin Point Laboratories Ltd reported a profit before tax of ₹145.97 crores, which decreased by 17.7% from the ₹177.27 crores reported in Q3FY25. Year-over-year, there is a 17.7% increase compared to the profit before tax of ₹123.97 crores in Q4FY24. The tax expenses for Q4FY25 amounted to ₹24.80 crores, reflecting a significant quarter-over-quarter decrease of 33.3% and a year-over-year increase of 8.7%. Consequently, the profit after tax for Q4FY25 was ₹121.23 crores, down by 13.5% from ₹140.07 crores in Q3FY25, but up 19.7% from ₹101.24 crores in Q4FY24. The earnings per share (EPS) for Q4FY25 stood at ₹15.90, marking a decline of 12.6% quarter-over-quarter and an increase of 19.5% year-over-year.
Operating Metrics
The financial performance of Caplin Point Laboratories Ltd in Q4FY25 showcases several key metrics. Total expenses for the quarter were ₹324.54 crores, which is a reduction of 6.5% from the previous quarter (Q3FY25) where expenses were ₹347.05 crores. Year-over-year, there is an increase of 17.3% from the expenses of ₹276.71 crores in Q4FY24. The company's operating metrics indicate a decrease in expenses on a quarterly basis, while showing an increase annually. These metrics provide insights into the financial management and operational efficiency of the company during the reported periods.
